Minerva NeurosciencesAktie
 
Mehr Daten anzeigen
ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Minerva Neurosciences, Inc. Investors of Important February 8 Deadline in Securities Class Action – NERV

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the "Class Period"), of the important February 8, 2021 lead …

Wertpapier:
Robbins Geller Rudman & Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline

Robbins Geller Rudman & Dowd LLP announces that purchasers of Minerva Neurosciences, Inc. (NASDAQ:NERV) common stock between May 15, 2017 and November 30, 2020, inclusive (the “Class Period”), have until February 8, 2021 to seek appointment as lead …

Wertpapier:

Nachrichten

ZeitTitel
02.01.21
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Minerva Neurosciences, Inc. Investors of Important Deadline in Securities Class Action; Investors with Losses in Excess of $100K Are Encouraged to Contact the Firm – NERV
22.12.20
Notice of Lead Plaintiff Deadline for Shareholders in the Minerva Neurosciences, Inc. Class Action Lawsuit
17.12.20
NERV Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Minerva Neurosciences, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: February 8, 2021
10.12.20
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
09.12.20
Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Minerva Neurosciences, Inc. – NERV
09.12.20
MINERVA NEUROSCIENCES ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Minerva Neurosciences, Inc. and Encourages Investors to Contact the Firm
08.12.20
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Minerva Neurosciences, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
01.12.20
Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone
09.11.20
Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference
02.11.20
Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates
26.10.20
Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020
09.09.20
Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
02.09.20
Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference
13.08.20
Minerva Neurosciences to Present at JMP Securities CNS Forum
03.08.20
Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates
Diskussionen

Minerva Neurosciences Forum

Die wichtigsten Links der Community
Börsenforum - der komplette Überblick
Alle Foren von Anfänger bis Zertifikate
Forum-Suche

Diskussionen

TitelNeuester Beitrag
Rebound-Chance nach verpassten Phase-3 Studienzielen
Erstellt: 30.05.20, 17:03 von Gustl24		04.12.20, 08:17
Webinar um 15:30 Uhr
Countdown
Countdown
00 Std.
28 Min.
25 Sek.
15:30 Uhr Webinar von GKFX Europe
DAX PROFESSIONALS - Die Woche im deutschen Leitindex
Was halten Sie von den neusten Entwicklungen zu Minerva Neurosciences?


Community

Meistdiskutierte Aktien (24h)

WertpapierBeiträge
DAX
182
NeutriSci International
114
Lyxor ETF MSCI World D €
98
Plug Power
92
Sernova
82
Gold
81
Halo Labs
81
BioNTech
65
Xiaomi Registered (B)
62
TAAT Lifestyle & Wellness
61